For the quarter ending 2026-03-31, NDRA had -$405,903 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,311,433 | -3,169,209 | -3,858,201 | - |
| Depreciation and amortization | 9,492 | 10,117 | 33,928 | - |
| Stock compensation expense | 574,451 | 12,878 | 144,722 | 171,809 |
| Changes in fair value of warrant liability | - | - | - | 470,674 |
| Net loss | - | - | - | -2,262,242 |
| Amortization of right of use assets | 30,223 | 29,415 | 28,603 | 55,231 |
| Fair value of vested advisory warrant | - | 665,030 | - | - |
| Digital asset staking compensation | 11,060 | 5,121 | - | - |
| Unrealized gain on change in fair value of digital assets | 738,177 | -995,161 | - | - |
| Realized gain on change in fair value of digital assets | 121,584 | - | - | - |
| Changes in fair value of warrant liability | 8,857 | -116,137 | -203,400 | - |
| Fixed assets write off | - | 0 | 0 | - |
| Inventory reserve | - | 0 | 0 | - |
| Warrant expense | - | 0 | 0 | - |
| Gain or loss on settlement of warrant exercise | - | 0 | 0 | - |
| Decrease in inventory | - | 0 | 0 | 0 |
| Decrease/(increase) in prepaid expenses | -390,817 | -49,069 | 210,361 | -159,873 |
| Increase/(decrease) in accounts payable and accrued liabilities | 79,908 | -49,937 | 223,095 | -59,871 |
| Depreciation and amortization | - | - | - | 23,142 |
| Fixed assets write off | - | - | - | 0 |
| Inventory reserve | - | - | - | 0 |
| Increase/(decrease) in lease liability | -31,146 | -32,977 | -32,163 | -24,112 |
| Net cash used in operating activities | -1,119,650 | -1,611,711 | -1,164,003 | -2,406,844 |
| Proceeds from sale of fixed assets | - | - | - | 0 |
| Purchases of fixed assets | - | 0 | 0 | 17,280 |
| Purchase of digital intangible assets | - | 3,000,000 | - | - |
| Proceeds from sale of fixed assets | - | 0 | 0 | - |
| Sale of digital intangible assets | 450,000 | - | - | - |
| Net cash provided by (used in) investing activities | 450,000 | -3,000,000 | 0 | -17,280 |
| Repayment of loan | - | - | - | 0 |
| Proceeds from warrant issuances and exercises | - | - | 0 | 0 |
| Proceeds from fundraising activities | - | 4,514,482 | - | - |
| Proceeds from issuance of common stock for cash | 263,747 | 65,557 | 149,466 | 1,003,218 |
| Proceeds from issuance of common stock for cashless warrant exercise - | - | 0 | - | - |
| Repayment of loan | - | 0 | 0 | - |
| Net cash provided by financing activities | 263,747 | 4,580,039 | 149,466 | 1,003,218 |
| Net increase (decrease) in cash | - | -31,672 | - | - |
| Net increase (decrease) in cash | -405,903 | -31,672 | -1,014,537 | -1,420,906 |
| Cash, beginning of period | - | 794,036 | 3,229,480 | - |
| Cash, end of period | - | 762,365 | 794,036 | - |
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)